Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 335

1.

Expression of L1 retrotransposon open reading frame protein 1 (L1ORF1p) in gynecologic cancers.

Zhouchunyang X, Cochrane DR, Tessier-Coutier B, Leung S, Karnezis AN, Cheng AS, Farnell DA, Magrill J, Schmidt D, Kommoss S, Kommoss FKF, Kommoss F, McAlpine JN, Gilks CB, Koebel M, Rabban JT, Huntsman DG.

Hum Pathol. 2019 Jun 17. pii: S0046-8177(19)30103-0. doi: 10.1016/j.humpath.2019.06.001. [Epub ahead of print]

PMID:
31220479
2.

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF; HGSC CRS Collaborative Network (Supplementary 1), Singh N.

Gynecol Oncol. 2019 May 19. pii: S0090-8258(19)31181-3. doi: 10.1016/j.ygyno.2019.04.679. [Epub ahead of print] Review.

3.

Two versus Four Immunostains for Lynch Syndrome Screening in Endometrial Carcinoma.

Niu BT, Hammond RFL, Leen SLS, Gilks CB, Singh N.

Histopathology. 2019 May 11. doi: 10.1111/his.13898. [Epub ahead of print]

PMID:
31077605
4.

DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors.

Karnezis AN, Wang Y, Keul J, Tessier-Cloutier B, Magrill J, Kommoss S, Senz J, Yang W, Proctor L, Schmidt D, Clement PB, Gilks CB, Huntsman DG, Kommoss F.

Am J Surg Pathol. 2019 May;43(5):628-638. doi: 10.1097/PAS.0000000000001232.

PMID:
30986800
5.

Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.

Britton H, Huang L, Lum A, Leung S, Shum K, Kale M, Burleigh A, Senz J, Yang W, McConechy M, Kommoss S, Brucker S, Talhouk A, Gilks CB, McAlpine JN.

Gynecol Oncol. 2019 Jun;153(3):487-495. doi: 10.1016/j.ygyno.2019.03.098. Epub 2019 Mar 25.

PMID:
30922603
6.

Diagnostic Accuracy in Fit-for-Purpose PD-L1 Testing.

Cheung CC, Lim HJ, Garratt J, Won J, Gilks CB, Torlakovic EE.

Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):251-257. doi: 10.1097/PAI.0000000000000734.

PMID:
30789848
7.

Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists.

Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, Parkash V, Carlson J, McCluggage WG, Gilks CB.

Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S64-S74. doi: 10.1097/PGP.0000000000000518. Review.

8.

High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.

Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, Irving JA, Malpica A, Matias-Guiu X, McCluggage WG, Mittal K, Oliva E, Parkash V, Rutgers JKL, Staats PN, Stewart CJR, Tornos C, Soslow RA.

Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S40-S63. doi: 10.1097/PGP.0000000000000491. Review.

9.

Issues in the Differential Diagnosis of Uterine Low-grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: Recommendations from the International Society of Gynecological Pathologists.

Rabban JT, Gilks CB, Malpica A, Matias-Guiu X, Mittal K, Mutter GL, Oliva E, Parkash V, Ronnett BM, Staats P, Stewart CJR, McCluggage WG.

Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S25-S39. doi: 10.1097/PGP.0000000000000512.

10.

Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma.

Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks CB, Anglesio MS, Nelson BH, McAlpine JN.

Clin Cancer Res. 2019 Apr 15;25(8):2537-2548. doi: 10.1158/1078-0432.CCR-18-3241. Epub 2018 Dec 6.

PMID:
30523022
11.

Performance Characteristics of Endometrial Sampling in Diagnosis of Endometrial Carcinoma.

Taraboanta C, Britton H, Plotkin A, Azordegan N, Clement PB, Gilks CB.

Int J Gynecol Pathol. 2018 Dec 3. doi: 10.1097/PGP.0000000000000569. [Epub ahead of print]

PMID:
30516616
12.

Histotype classification of ovarian carcinoma: A comparison of approaches.

Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, Kelemen LE, Nazeran TM, Gilks CB, Harris HR, Huntsman DG, Schildkraut JM, Rossing MA, Köbel M, Doherty JA.

Gynecol Oncol. 2018 Oct;151(1):53-60. doi: 10.1016/j.ygyno.2018.08.016. Epub 2018 Aug 16.

PMID:
30121132
13.

Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles.

Magrill J, Karnezis AN, Tessier-Cloutier B, Talhouk A, Kommoss S, Cochrane D, Chow C, Cheng A, Soslow R, Hauptmann S, du Bois A, Pfisterer J, Gilks CB, Huntsman DG, Kommoss F.

Int J Gynecol Pathol. 2018 Jul 27. doi: 10.1097/PGP.0000000000000538. [Epub ahead of print]

PMID:
30059451
14.

L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.

Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, Gilks CB, Huntsman DG, Krämer B, Brucker SY, McAlpine JN, Kommoss S.

Br J Cancer. 2018 Aug;119(4):480-486. doi: 10.1038/s41416-018-0187-6. Epub 2018 Jul 27.

PMID:
30050154
15.

Correction: TERT promoter mutation in adult granulosa cell tumor of the ovary.

Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, Bashashati A, Keul J, Wong A, Norris K, Brucker SY, Taran FA, Krämer B, Staebler A, van Meurs H, Oliva E, Shah SP, Kommoss S, Kommoss F, Gilks CB, Baird DM, Huntsman DG.

Mod Pathol. 2019 Apr;32(4):593. doi: 10.1038/s41379-018-0085-8.

PMID:
29968850
16.

Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions.

Köbel M, Luo L, Grevers X, Lee S, Brooks-Wilson A, Gilks CB, Le ND, Cook LS.

Int J Gynecol Pathol. 2019 Jul;38(4):353-362. doi: 10.1097/PGP.0000000000000530.

PMID:
29901523
17.

Artefactual punctate MLH1 staining can lead to erroneous reporting of isolated PMS2 loss.

Niu BT, Hammond RFL, Leen SLS, Faruqi AZ, Trevisan G, Gilks CB, Singh N.

Histopathology. 2018 Oct;73(4):703-705. doi: 10.1111/his.13663. Epub 2018 Jul 12. No abstract available.

PMID:
29852531
18.

Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.

Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl A, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan ANC, Nielsen CB, Huebner C, Tessier-Cloutier B, Anglesio MS, Bouchard-Côté A, Yuan Y, Wasserman WW, Gilks CB, Karnezis AN, Aparicio S, McAlpine JN, Huntsman DG, Holt RA, Nelson BH, Shah SP.

Cell. 2018 Jun 14;173(7):1755-1769.e22. doi: 10.1016/j.cell.2018.03.073. Epub 2018 May 10.

19.

DICER1 hot-spot mutations in ovarian gynandroblastoma.

Wang Y, Karnezis AN, Magrill J, Tessier-Cloutier B, Lum A, Senz J, Gilks CB, McCluggage WG, Huntsman DG, Kommoss F.

Histopathology. 2018 Aug;73(2):306-313. doi: 10.1111/his.13630. Epub 2018 Jun 5.

PMID:
29660837
20.

Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.

Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG.

Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S123-S131. doi: 10.1097/PGP.0000000000000488. Review.

21.

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.

Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR, Gonzalez C, Ganesan R, Steele JC, Harrison BT, Oliva E, Vidal A, Matias-Guiu X, Abu-Rustum NR, Levine DA, Gilks CB, Soslow RA.

Am J Surg Pathol. 2018 May;42(5):561-568. doi: 10.1097/PAS.0000000000001020.

22.

TERT promoter mutation in adult granulosa cell tumor of the ovary.

Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, Bashashati A, Keul J, Wong A, Norris K, Brucker SY, Taran FA, Krämer B, Staebler A, van Meurs H, Oliva E, Shah SP, Kommoss S, Kommoss F, Gilks CB, Baird DM, Huntsman DG.

Mod Pathol. 2018 Jul;31(7):1107-1115. doi: 10.1038/s41379-018-0007-9. Epub 2018 Feb 15. Erratum in: Mod Pathol. 2018 Jul 3;:.

23.

Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series.

Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, Yang W, Lum A, Krämer B, Taran F, Staebler A, Lax S, Brucker SY, Huntsman DG, Gilks CB, McAlpine JN, Talhouk A.

Ann Oncol. 2018 May 1;29(5):1180-1188. doi: 10.1093/annonc/mdy058.

PMID:
29432521
24.

Bartholin Gland Carcinoma: Clinicopathologic Features, Including p16 Expression and Clinical Outcome.

Nazeran T, Cheng AS, Karnezis AN, Tinker AV, Gilks CB.

Int J Gynecol Pathol. 2019 Mar;38(2):189-195. doi: 10.1097/PGP.0000000000000489.

PMID:
29406447
25.

Canadian Consensus-based and Evidence-based Guidelines for Benign Endometrial Pathology Reporting in Biopsy Material.

Parra-Herran C, Cesari M, Djordjevic B, Grondin K, Kinloch M, Köbel M, Pirzada A, Plotkin A, Gilks CB.

Int J Gynecol Pathol. 2019 Mar;38(2):119-127. doi: 10.1097/PGP.0000000000000481.

PMID:
29369922
26.

Synchronous tumours of the female reproductive tract.

Gilks CB, Kommoss F.

Pathology. 2018 Feb;50(2):214-221. doi: 10.1016/j.pathol.2017.10.007. Epub 2017 Dec 14. Review.

PMID:
29249564
27.

Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging.

Singh N, Faruqi A, Kommoss F, McCluggage WG, Trevisan G, Senz J, Lum A, Gilks CB, Anglesio M.

Mod Pathol. 2018 Apr;31(4):652-659. doi: 10.1038/modpathol.2017.159. Epub 2017 Nov 17.

28.

Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.

Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, Kobel M, Lee CH, Huntsman DG, Talhouk A, Kommoss F, Gilks CB, McAlpine JN.

J Pathol Clin Res. 2017 Oct 14;3(4):279-293. doi: 10.1002/cjp2.82. eCollection 2017 Oct.

29.

Pathology of Ovarian Cancer: Recent Insights Unveiling Opportunities in Prevention.

Kommoss F, Gilks CB.

Clin Obstet Gynecol. 2017 Dec;60(4):686-696. doi: 10.1097/GRF.0000000000000314. Review.

PMID:
28990983
30.

Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas.

Kumar A, Le N, Gilks CB, Santos JL, Wong F, Swenerton K, Hoskins PJ, McAlpine JN, Tinker AV.

Int J Gynecol Cancer. 2017 Nov;27(9):1819-1825. doi: 10.1097/IGC.0000000000001124.

PMID:
28930809
31.

Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage.

Singh N, Benson JL, Gan C, Anglesio M, Arora R, Faruqi AZ, Hirschowitz L, Kommoss F, Scott K, Trevisan G, Leen SLS, Wilkinson N, Gilks CB, McCluggage WG.

Int J Gynecol Pathol. 2018 Jul;37(4):324-330. doi: 10.1097/PGP.0000000000000429.

PMID:
28787323
32.

Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries.

Anglesio MS, O'Neill CJ, Senz J, Gilks CB, McCluggage WG.

Histopathology. 2017 Dec;71(6):1014-1017. doi: 10.1111/his.13327. Epub 2017 Sep 22. No abstract available.

PMID:
28746984
33.

Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?

Cochrane DR, Tessier-Cloutier B, Lawrence KM, Nazeran T, Karnezis AN, Salamanca C, Cheng AS, McAlpine JN, Hoang LN, Gilks CB, Huntsman DG.

J Pathol. 2017 Sep;243(1):26-36. doi: 10.1002/path.4934. Epub 2017 Aug 7.

PMID:
28678427
34.

Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.

Proctor L, Pradhan M, Leung S, Cheng A, Lee CH, Soslow RA, Gilks CB, Talhouk A, McAlpine JM, Danielsen HE, Hoang LN.

Gynecol Oncol. 2017 Sep;146(3):596-602. doi: 10.1016/j.ygyno.2017.06.020. Epub 2017 Jun 21.

PMID:
28647100
35.

A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy.

Casey L, Köbel M, Ganesan R, Tam S, Prasad R, Böhm S, Lockley M, Jeyarajah AJ, Brockbank E, Faruqi A, Gilks CB, Singh N.

Histopathology. 2017 Nov;71(5):736-742. doi: 10.1111/his.13272. Epub 2017 Aug 7.

PMID:
28570008
36.

Cancer-Associated Mutations in Endometriosis without Cancer.

Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM.

N Engl J Med. 2017 May 11;376(19):1835-1848. doi: 10.1056/NEJMoa1614814.

37.

High-grade serous carcinoma of tubo-ovarian origin: recent developments.

Singh N, McCluggage WG, Gilks CB.

Histopathology. 2017 Sep;71(3):339-356. doi: 10.1111/his.13248. Epub 2017 Jul 18. Review.

PMID:
28477361
38.

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.

Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Senz J, Prentice LM, Karnezis AN, Lai D, Aniba MR, Zhang AW, Shumansky K, Siu C, Wan A, McConechy MK, Li-Chang H, Tone A, Provencher D, de Ladurantaye M, Fleury H, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mungall AJ, Moore R, Marra MA, Gilks CB, Mes-Masson AM, McAlpine JN, Aparicio S, Huntsman DG, Shah SP.

Nat Genet. 2017 Jun;49(6):856-865. doi: 10.1038/ng.3849. Epub 2017 Apr 24.

PMID:
28436987
39.

Molecular subtyping of mammary-like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas.

Tessier-Cloutier B, Asleh-Aburaya K, Shah V, McCluggage WG, Tinker A, Gilks CB.

Histopathology. 2017 Sep;71(3):446-452. doi: 10.1111/his.13239. Epub 2017 Jun 16.

PMID:
28418164
40.

HPV-independent Differentiated Vulvar Intraepithelial Neoplasia (dVIN) is Associated With an Aggressive Clinical Course.

McAlpine JN, Kim SY, Akbari A, Eshragh S, Reuschenbach M, von Knebel Doeberitz M, Prigge ES, Jordan S, Singh N, Miller DM, Gilks CB.

Int J Gynecol Pathol. 2017 Nov;36(6):507-516. doi: 10.1097/PGP.0000000000000375.

PMID:
28319571
41.

Tubal origin of ovarian high-grade serous carcinoma-time to let go of the wrong end of the stick.

Singh N, Gilks CB.

BJOG. 2017 May;124(6):879. doi: 10.1111/1471-0528.14542. Epub 2017 Mar 15. No abstract available.

42.

Ovarian carcinoma histotype in Lynch syndrome.

Gilks CB, Clarke BA, Foulkes WD.

Gynecol Oncol Rep. 2017 Mar 16;20:140-141. doi: 10.1016/j.gore.2017.03.009. eCollection 2017 May. No abstract available.

43.

Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study.

McAlpine JN, Leung SCY, Cheng A, Miller D, Talhouk A, Gilks CB, Karnezis AN.

Histopathology. 2017 Aug;71(2):238-246. doi: 10.1111/his.13205. Epub 2017 May 23.

PMID:
28257152
44.

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.

Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM.

Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21.

45.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories.

Torlakovic EE, Cheung CC, D'Arrigo C, Dietel M, Francis GD, Gilks CB, Hall JA, Hornick JL, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Vyberg M, Zhou X, Taylor CR; From the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and International Quality Network for Pathology (IQN Path).

Appl Immunohistochem Mol Morphol. 2017 Mar;25(3):151-159. doi: 10.1097/PAI.0000000000000470.

PMID:
28187030
46.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics.

Torlakovic EE, Cheung CC, D'Arrigo C, Dietel M, Francis GD, Gilks CB, Hall JA, Hornick JL, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Vyberg M, Zhou X, Taylor CR; From the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and International Quality Network for Pathology (IQN Path).

Appl Immunohistochem Mol Morphol. 2017 Feb;25(2):79-85. doi: 10.1097/PAI.0000000000000444. Review.

PMID:
28182587
47.

Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium.

Köbel M, Tessier-Cloutier B, Leo J, Hoang LN, Gilks CB, Soslow RA, Delair D, Stewart CJR, Lee CH.

Int J Gynecol Pathol. 2017 Nov;36(6):555-561. doi: 10.1097/PGP.0000000000000369.

PMID:
28114191
48.

Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.

Hoang LN, Kinloch MA, Leo JM, Grondin K, Lee CH, Ewanowich C, Köbel M, Cheng A, Talhouk A, McConechy M, Huntsman DG, McAlpine JN, Soslow RA, Gilks CB.

Am J Surg Pathol. 2017 Feb;41(2):245-252. doi: 10.1097/PAS.0000000000000764.

PMID:
28079598
49.

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.

Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN.

Cancer. 2017 Mar 1;123(5):802-813. doi: 10.1002/cncr.30496. Epub 2017 Jan 6.

50.

The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century.

Singh N, Gilks CB.

Histopathology. 2017 Jan;70(1):56-69. doi: 10.1111/his.13080. Review.

PMID:
27960241

Supplemental Content

Loading ...
Support Center